Carmel Pezaro

4.1k total citations
60 papers, 2.2k citations indexed

About

Carmel Pezaro is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Carmel Pezaro has authored 60 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 55 papers in Pulmonary and Respiratory Medicine, 19 papers in Oncology and 19 papers in Cancer Research. Recurrent topics in Carmel Pezaro's work include Prostate Cancer Treatment and Research (48 papers), Radiopharmaceutical Chemistry and Applications (18 papers) and Prostate Cancer Diagnosis and Treatment (12 papers). Carmel Pezaro is often cited by papers focused on Prostate Cancer Treatment and Research (48 papers), Radiopharmaceutical Chemistry and Applications (18 papers) and Prostate Cancer Diagnosis and Treatment (12 papers). Carmel Pezaro collaborates with scholars based in United Kingdom, Australia and United States. Carmel Pezaro's co-authors include Johann S. de Bono, Gerhardt Attard, Aurelius Omlin, Diletta Bianchini, Roberta Ferraldeschi, David Lorente, Deborah Mukherji, Shahneen Sandhu, Andrea Zivi and Suzanne Carreira and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Carmel Pezaro

60 papers receiving 2.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Carmel Pezaro United Kingdom 21 1.8k 792 631 498 466 60 2.2k
Mary B. Todd United States 18 2.1k 1.2× 691 0.9× 739 1.2× 605 1.2× 428 0.9× 54 2.5k
Diletta Bianchini United Kingdom 22 1.6k 0.9× 768 1.0× 755 1.2× 659 1.3× 356 0.8× 68 2.1k
Daniel Petrylak United States 6 1.9k 1.1× 592 0.7× 726 1.2× 813 1.6× 453 1.0× 8 2.4k
David Lorente Spain 28 1.8k 1.0× 1.1k 1.3× 653 1.0× 1.2k 2.4× 594 1.3× 100 2.9k
Angela Lopez‐Gitlitz United States 14 1.8k 1.0× 587 0.7× 676 1.1× 368 0.7× 235 0.5× 62 1.9k
Julie S. Larsen United States 13 1.3k 0.7× 416 0.5× 494 0.8× 322 0.6× 303 0.7× 31 1.8k
Consuelo Buttigliero Italy 23 1.0k 0.6× 397 0.5× 247 0.4× 692 1.4× 411 0.9× 91 1.7k
Martin Boegemann Germany 19 1.2k 0.6× 388 0.5× 630 1.0× 430 0.9× 228 0.5× 90 1.4k
Peter F.A. Mulders Netherlands 22 1.5k 0.8× 584 0.7× 278 0.4× 228 0.5× 567 1.2× 43 1.9k
Kim Chi Canada 20 799 0.4× 520 0.7× 229 0.4× 636 1.3× 872 1.9× 49 1.9k

Countries citing papers authored by Carmel Pezaro

Since Specialization
Citations

This map shows the geographic impact of Carmel Pezaro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carmel Pezaro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carmel Pezaro more than expected).

Fields of papers citing papers by Carmel Pezaro

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carmel Pezaro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carmel Pezaro. The network helps show where Carmel Pezaro may publish in the future.

Co-authorship network of co-authors of Carmel Pezaro

This figure shows the co-authorship network connecting the top 25 collaborators of Carmel Pezaro. A scholar is included among the top collaborators of Carmel Pezaro based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carmel Pezaro. Carmel Pezaro is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lawrence, Mitchell G., Laura H. Porter, David Pook, et al.. (2021). CX-5461 Sensitizes DNA Damage Repair–proficient Castrate-resistant Prostate Cancer to PARP Inhibition. Molecular Cancer Therapeutics. 20(11). 2140–2150. 17 indexed citations
2.
Qu, Liang G., Hady Wardan, Ian D. Davis, et al.. (2019). Circulating oestrogen receptor mutations and splice variants in advanced prostate cancer. British Journal of Urology. 124(S1). 50–56. 12 indexed citations
3.
Li, Henry, et al.. (2017). Searching for a written patient feedback instrument for patient–medical student consultations. Advances in Medical Education and Practice. Volume 8. 171–178. 7 indexed citations
4.
Lorente, David, Praful Ravi, Niven Mehra, et al.. (2016). Interrogating Metastatic Prostate Cancer Treatment Switch Decisions: A Multi-institutional Survey. European Urology Focus. 4(2). 235–244. 15 indexed citations
5.
6.
Massard, C., Joaquı́n Mateo, Yohann Loriot, et al.. (2016). Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone. Annals of Oncology. 28(1). 90–95. 20 indexed citations
7.
Mukherji, Deborah, Aurelius Omlin, Carmel Pezaro, Ali Shamseddine, & Johann S. de Bono. (2014). Metastatic castration-resistant prostate cancer (CRPC): preclinical and clinical evidence for the sequential use of novel therapeutics. Cancer and Metastasis Reviews. 33(2-3). 555–566. 48 indexed citations
8.
Loriot, Yohann, Diletta Bianchini, E. Ileana, et al.. (2013). Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). Annals of Oncology. 24(7). 1807–1812. 273 indexed citations
9.
Pezaro, Carmel, Deborah Mukherji, Nina Tunariu, et al.. (2013). Sarcopenia and change in body composition following maximal androgen suppression with abiraterone in men with castration-resistant prostate cancer. British Journal of Cancer. 109(2). 325–331. 36 indexed citations
10.
Omlin, Aurelius, Carmel Pezaro, Deborah Mukherji, et al.. (2013). Improved Survival in a Cohort of Trial Participants with Metastatic Castration-resistant Prostate Cancer Demonstrates the Need for Updated Prognostic Nomograms. European Urology. 64(2). 300–306. 69 indexed citations
11.
Mukherji, Deborah, Carmel Pezaro, Ali Shamseddine, & Johann S. de Bono. (2013). New treatment developments applied to elderly patients with advanced prostate cancer. Cancer Treatment Reviews. 39(6). 578–583. 15 indexed citations
12.
Pezaro, Carmel, Aurelius Omlin, David Lorente, & Johann S. de Bono. (2013). Management of Patients with Castration-Resistant Disease. Hematology/Oncology Clinics of North America. 27(6). 1243–1260. 4 indexed citations
13.
Bianchini, Diletta, Aurelius Omlin, Carmel Pezaro, et al.. (2013). First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer. British Journal of Cancer. 109(10). 2579–2586. 72 indexed citations
14.
Omlin, Aurelius, Carmel Pezaro, S. Zaidi, et al.. (2013). Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer. British Journal of Cancer. 109(5). 1079–1084. 15 indexed citations
15.
Hay, C. R. M., Angela E. Taylor, Anna Wingate, et al.. (2012). Interactions of Abiraterone, Eplerenone, and Prednisolone with Wild-type and Mutant Androgen Receptor: A Rationale for Increasing Abiraterone Exposure or Combining with MDV3100. Cancer Research. 72(9). 2176–2182. 201 indexed citations
16.
17.
Yap, Timothy A., Carmel Pezaro, & Johann S. de Bono. (2012). Cabazitaxel in metastatic castration-resistant prostate cancer. Expert Review of Anticancer Therapy. 12(9). 1129–1136. 16 indexed citations
18.
Pezaro, Carmel, Deborah Mukherji, & Johann S. de Bono. (2011). Abiraterone acetate: redefining hormone treatment for advanced prostate cancer. Drug Discovery Today. 17(5-6). 221–226. 25 indexed citations
19.
Pezaro, Carmel, Mark Rosenthal, Howard Gurney, et al.. (2009). An Open-Label, Single-Arm Phase Two Trial of Gefitinib in Patients With Advanced or Metastatic Castration-Resistant Prostate Cancer. American Journal of Clinical Oncology. 32(4). 338–341. 42 indexed citations
20.
Pezaro, Carmel & Ian D. Davis. (2008). Targeted Therapies in the Treatment of Renal Cell Carcinoma. Current Medicinal Chemistry. 15(12). 1166–1174. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mary B. Todd Breakdown of academic impact, for papers by Diletta Bianchini Breakdown of academic impact, for papers by Daniel Petrylak Breakdown of academic impact, for papers by David Lorente Breakdown of academic impact, for papers by Angela Lopez‐Gitlitz Breakdown of academic impact, for papers by Julie S. Larsen Breakdown of academic impact, for papers by Consuelo Buttigliero Breakdown of academic impact, for papers by Martin Boegemann Breakdown of academic impact, for papers by Peter F.A. Mulders Breakdown of academic impact, for papers by Kim Chi
Rankless by CCL
2026